Recursion Pharmaceuticals (RXRX)
3.64
-0.02 (0.55%)
Upcoming Events
Latest Headlines
Recursion Pharmaceuticals (RXRX) PT Raised to $5.90 at Morgan Stanley
October 16, 2026 8:43 AM - StreetInsider
Form 424B5 RECURSION PHARMACEUTICAL
October 15, 2026 5:31 PM - SEC Filing
Form 8-K RECURSION PHARMACEUTICAL For: Oct 15
October 15, 2026 8:47 AM - SEC Filing
Sanofi options Recursion drug candidate, triggering $10M payment
October 15, 2026 8:46 AM - StreetInsider
Recursion Announces Sanofi Options Potential First-in-Class Immunology Development Candidate from Their Collaboration
October 15, 2026 8:45 AM - Globe NewsWire
Recursion prices $200M stock offering at $3.25 per share
October 15, 2026 8:31 AM - StreetInsider
Recursion Announces Pricing of $200 Million Underwritten Offering of Class A Common Stock
October 15, 2026 8:30 AM - StreetInsider
Recursion raises $200M, reports clinical updates and Sanofi milestone
October 15, 2026 8:23 AM - StreetInsider
Recursion Announces $200 Million Oversubscribed Follow-On Offering, Clinical Data Updates, and Partnership Milestone
October 15, 2026 8:22 AM - Globe NewsWire
Form 424B5 RECURSION PHARMACEUTICAL
October 15, 2026 8:20 AM - SEC Filing
FTC seeks contempt finding against Martin Shkreli for alleged pharma ban violation
October 13, 2026 8:54 AM - StreetInsider
Form 4 RECURSION PHARMACEUTICAL For: Oct 06 Filed by: Borgeson Blake
October 7, 2026 6:09 PM - SEC Filing
Form 4 RECURSION PHARMACEUTICAL For: Oct 06 Filed by: HERSHBERG ROBERT
October 7, 2026 6:08 PM - SEC Filing
Form 144 RECURSION PHARMACEUTICAL Filed by: Borgeson Blake
October 6, 2026 11:48 AM - SEC Filing
Form 144 RECURSION PHARMACEUTICAL Filed by: HERSHBERG ROBERT
October 6, 2026 11:09 AM - SEC Filing
Form 4 RECURSION PHARMACEUTICAL For: Oct 01 Filed by: Dar Zavain
October 2, 2026 6:18 PM - SEC Filing
Form 4 RECURSION PHARMACEUTICAL For: Oct 01 Filed by: Li Dean Y
October 2, 2026 6:17 PM - SEC Filing
Tempus AI and Recursion extend data deal, add RNA model license
September 21, 2026 9:14 AM - StreetInsider
Tempus and Recursion Extend Existing Data License Agreement and Enter New License Agreement for Recursion’s RNA Foundation Model
September 21, 2026 9:14 AM - BizWire
Form 8-K RECURSION PHARMACEUTICAL For: Sep 15
September 21, 2026 9:05 AM - SEC Filing
Form 4 RECURSION PHARMACEUTICAL For: Sep 15 Filed by: Taylor Ben R
September 16, 2026 5:52 PM - SEC Filing
Form 4 RECURSION PHARMACEUTICAL For: Sep 08 Filed by: Khan Najat
September 10, 2026 5:56 PM - SEC Filing
Form 144 RECURSION PHARMACEUTICAL Filed by: Gibson Christopher
August 21, 2026 11:27 AM - SEC Filing
Form 144 RECURSION PHARMACEUTICAL Filed by: Gibson Christopher
August 20, 2026 11:32 AM - SEC Filing
Form 144 RECURSION PHARMACEUTICAL Filed by: Gibson Christopher
August 19, 2026 11:55 AM - SEC Filing
Form 4 RECURSION PHARMACEUTICAL For: Aug 17 Filed by: Khan Najat
August 18, 2026 5:45 PM - SEC Filing
Form 4 RECURSION PHARMACEUTICAL For: Aug 17 Filed by: Taylor Ben R
August 18, 2026 5:44 PM - SEC Filing
Form 4 RECURSION PHARMACEUTICAL For: Aug 17 Filed by: Hallett David
August 18, 2026 5:44 PM - SEC Filing
Form 144 RECURSION PHARMACEUTICAL Filed by: Gibson Christopher
August 18, 2026 5:15 PM - SEC Filing
Recursion Pharmaceuticals (RXRX) PT Lowered to $5.30 at Morgan Stanley
August 17, 2026 8:58 AM - StreetInsider
Form 144 RECURSION PHARMACEUTICAL Filed by: Gibson Christopher
August 13, 2026 12:58 PM - SEC Filing
Form 144 RECURSION PHARMACEUTICAL Filed by: Gibson Christopher
August 12, 2026 11:57 AM - SEC Filing
Form 144 RECURSION PHARMACEUTICAL Filed by: Gibson Christopher
August 10, 2026 4:59 PM - SEC Filing
Form 144 RECURSION PHARMACEUTICAL Filed by: Gibson Christopher
August 7, 2026 12:43 PM - SEC Filing
Form SCHEDULE 13G RECURSION PHARMACEUTICAL Filed by: STATE STREET CORP
August 7, 2026 10:49 AM - SEC Filing
Form 4 RECURSION PHARMACEUTICAL For: Aug 04 Filed by: Borgeson Blake
August 6, 2026 5:09 PM - SEC Filing
Recursion Pharmaceuticals, Inc. (RXRX) Misses Q2 EPS by 1c
August 5, 2026 6:47 AM - StreetInsider
Form 10-Q RECURSION PHARMACEUTICAL For: Jun 30
August 5, 2026 6:33 AM - SEC Filing
Form 8-K RECURSION PHARMACEUTICAL For: Aug 05
August 5, 2026 6:32 AM - SEC Filing
Recursion Reports Second Quarter Financial Results; Genentech Options First Neuroscience Target into Early Discovery Program
August 5, 2026 6:30 AM - StreetInsider
Form 144 RECURSION PHARMACEUTICAL Filed by: Borgeson Blake
August 4, 2026 1:37 PM - SEC Filing
Form 144 RECURSION PHARMACEUTICAL Filed by: Gibson Christopher
August 4, 2026 10:35 AM - SEC Filing
Recursion to Participate in Upcoming Investor Conferences
August 4, 2026 8:00 AM - Globe NewsWire
Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules
July 31, 2026 4:30 PM - StreetInsider
Form SCHEDULE 13G RECURSION PHARMACEUTICAL Filed by: VANGUARD PORTFOLIO MANAGEMENT LLC
July 31, 2026 11:40 AM - SEC Filing
Form SCHEDULE 13G RECURSION PHARMACEUTICAL Filed by: VANGUARD CAPITAL MANAGEMENT LLC
July 31, 2026 10:42 AM - SEC Filing
Form 144 RECURSION PHARMACEUTICAL Filed by: Gibson Christopher
July 30, 2026 4:11 PM - SEC Filing
Form 144 RECURSION PHARMACEUTICAL Filed by: Gibson Christopher
July 29, 2026 4:10 PM - SEC Filing
Form SCHEDULE 13G/A RECURSION PHARMACEUTICAL Filed by: BlackRock, Inc.
July 29, 2026 3:22 PM - SEC Filing
Recursion to Report Second Quarter 2026 Business Updates and Financial Results on August 5th
July 29, 2026 8:30 AM - StreetInsider
Form 144 RECURSION PHARMACEUTICAL Filed by: Gibson Christopher
July 27, 2026 4:16 PM - SEC Filing
Full Article List
